eczema

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

NEW YORK, Dec. 27, 2025, 12:57 p.m. ET — Market closed (weekend) Healthcare stocks are heading into the final trading days of 2025 with a rare mix of “defensive” support and headline-driven volatility—exactly the combination that can matter most when

27 December 2025

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering

9 December 2025

Biotechnology · Healthcare News · Investment · Pharmaceutical Industry · Stock Market

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high

8 December 2025

Biotech News · Eczema Research · Investing · NASDAQ:KYMR · Pharmaceutical Industry · Stock Market